Welcome to our dedicated page for Inventiva S.A. SEC filings (Ticker: IVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Inventiva S.A. filings document a foreign private issuer and ADR program tied to a clinical-stage biopharmaceutical company developing oral therapies for MASH. Form 6-K reports furnish press releases and meeting notices covering lanifibranor development, annual and preliminary financial results, R&D expense trends, cash resources, revenues, and financing activity.
The company's regulatory disclosures also cover governance and shareholder voting matters, annual general meeting materials, leadership and organizational changes, material agreements, capital-structure disclosures, and portfolio actions including the completed sale of odiparcil. These records connect Inventiva's drug-development focus with its reporting obligations as a France-based issuer listed through American depositary shares.
Inventiva has completed its warrant restructuring with the European Investment Bank by issuing 15,677,573 new EIB warrants at a subscription and exercise price of €0.01 each and cancelling all remaining legacy Tranche B warrants.
Each new warrant allows subscription for one ordinary share and, if fully exercised, would represent about 6.5% of Inventiva’s current share capital on a non-diluted basis. The new instruments remove the specific contractual anti-dilution protections and put option embedded in the legacy EIB warrants, simplifying the capital structure and limiting future dilution from this source.
After these changes, Inventiva’s share capital on a non-diluted basis totals 236,280,202 shares, with free float accounting for 55.0% of shares. On a fully diluted basis, including the new EIB warrants and other instruments, the share count would be 433,608,437 shares, with free float at 47.0%. The new EIB warrants are exercisable from August 30, 2026 until January 4, 2036 and will be held in registered form, not listed on any market. Management frames this refinancing step as part of broader efforts to optimize capital structure and support ongoing Phase 3 development of lanifibranor for MASH.
Inventiva S.A. reported the results of its Combined Shareholders’ General Meeting held on June 30, 2026. Shareholders voted on a wide range of ordinary and extraordinary resolutions, with a quorum of 71.874% based on 236,280,202 shares with voting rights.
All resolutions were adopted except the 31st resolution, which would have authorized share capital increases reserved for members of a company savings plan; it was rejected, with 45.94% of votes in favor and 54.06% against, in line with a negative recommendation from the Board of Directors. The meeting also approved, without modification, the compensation policy for corporate officers as described in Inventiva’s 2025 Universal Registration Document and related materials.
Inventiva S.A. reports major balance sheet moves and amendments to its new debt financing. The company repaid in full its loans from the European Investment Bank and repurchased a portion of the related EIB warrants, as part of a broader “Combined Transaction”. EIB waived early prepayment fees that would otherwise have applied.
On June 12, 2026 Inventiva issued Tranche A Convertible Bonds and Tranche B Amortized Bonds to funds managed by BlackRock and Claret Capital for initial gross proceeds of €75 million and net proceeds of €71,298,750, following a registered equity offering of 27,272,727 ADSs at $4.40 per ADS. The Tranche A Convertible Bonds carry a conversion price of €5.2893 per share, implying a conversion ratio of 0.18907 new ordinary share per €1 bond. Concurrently, the company issued Lenders’ Warrants with an exercise price of €4.1559 per share. Inventiva also amended its Subscription Agreement to refine the monthly testing of a €30.0 million minimum cash covenant linked to a €2.0 billion market capitalization trigger and to formalize bondholder representation for Tranches B and C.
Inventiva S.A. has called an Ordinary and Extraordinary General Meeting for June 30, 2026 to approve 2025 accounts and reset its financing toolkit. The statutory financial statements show a net accounting loss of EUR 207,965,630.56, which will be carried forward, bringing accumulated losses to EUR 583,594,899.42. Shareholders are asked to approve extensive authorizations for share issues with and without preemptive rights, debt securities issuances up to EUR 500,000,000, and a share buyback program for up to 10% of the share capital.
The agenda also includes multiple equity-based compensation plans, director elections and compensation policies, and technical updates to the bylaws. A key item notes that shareholders’ equity has fallen below half of share capital; shareholders resolve not to dissolve the company and to restore equity within the legal timeframe. In addition, the meeting will vote on issuing up to 15,677,573 new EIB share subscription warrants at an exercise price of EUR 0.01 each, replacing earlier, more protective EIB warrants as part of a wider refinancing of a EUR 50 million loan.
Inventiva S.A. is calling shareholders to a Combined General Meeting on June 30, 2026 in Paris and has made all preparatory documents available on its website and at its registered office.
The agenda has been expanded with a 39th resolution linked to a master agreement signed with the European Investment Bank. Inventiva plans to fully repay existing EIB loans, repurchase and cancel certain existing EIB warrants for an aggregate price of €50 million, and issue new warrants to the EIB on more standard terms, subject to shareholder approval at the meeting or, if needed, at a later meeting held by October 31, 2026.
Inventiva S.A. has informed investors that it has started mailing a proxy card and voting instructions to beneficial owners of its American Depositary Shares for its Ordinary and Extraordinary General Meeting. The meeting will take place on June 30, 2026 at 2 p.m. in Paris, France.
ADS holders can review the meeting materials on the company’s website or request free physical copies by mail. They may submit their votes by returning a completed voting form in a postage-paid envelope and are encouraged to consult their brokers for detailed voting guidance.
Inventiva S.A. has launched a comprehensive refinancing to support its MASH program and upcoming Phase 3 NATiV3 readout. The company is issuing 27,272,727 ADSs at $4.40 each, raising expected net proceeds of about $110.8 million (€95.2 million). It will use this cash, together with new debt, to fully repay its approximately €63 million European Investment Bank loan and repurchase a portion of related warrants that could otherwise convert into 38,360,540 shares.
Inventiva also agreed a secured structured debt facility with BlackRock and Claret of up to €130 million in committed tranches, plus a €20 million uncommitted tranche, with an initial €75 million draw. The debt carries fixed interest near 9.9%, runs to 2030, and is backed by key assets, including lanifibranor patents. Lenders receive equity-linked warrants, and the financing includes covenants and default triggers tied to NATiV3 Phase 3 results and market capitalization. Assuming completion of the equity raise, EIB transactions and Tranches A and B, Inventiva expects to fund operations into late Q2 2027, potentially into early Q1 2028 if all additional financing elements, including Tranche C and existing Tranche 3 warrants, are fully utilized.
We are offering 27,272,727 ADSs, each representing one ordinary share. The offering price is $4.40 per ADS for gross proceeds of $119,999,999 and estimated net proceeds of approximately $110.8M (€95.2M). We currently intend to use the net proceeds to repay in full our EIB loans and, together with proceeds from a new debt financing, to fund the repurchase of a portion of the EIB warrants; remaining funds under that debt commitment would fund continued development and potential commercialization of lanifibranor and general corporate purposes. The offering and related financings are interlinked: the Subscription Agreement with BlackRock and Claret and the EIB Master Agreement are conditioned on this equity financing and certain other conditions, and Tranche A/B initial debt closings are expected in mid-June 2026, subject to those conditions.
Inventiva S.A. reported its first quarter 2026 financial information, focusing on cash resources and runway for its MASH program. As of March 31, 2026, cash and cash equivalents were €75.0 million and short-term deposits were €121.5 million, compared with €99.3 million and €131.6 million as of December 31, 2025. The cash use mainly reflects planned spending on the lanifibranor development program.
Based on its current business plan, Inventiva estimates that its cash, cash equivalents and short-term deposits should fund operations until the middle of the first quarter of 2027. If Tranche 3 warrants from its structured financing are fully exercised for up to €116.0 million, the company estimates funding could extend to the middle of the third quarter of 2027, although exercise is not guaranteed. Inventiva reported no revenue for the first quarter of 2026, consistent with the first quarter of 2025, and highlighted topline NATiV3 Phase 3 results as an anticipated milestone in the fourth quarter of 2026.
Inventiva S.A. is convening an ordinary and extraordinary general meeting on June 30, 2026 in Paris and sets out extensive resolutions on 2025 results, governance and future financing tools. Shareholders are asked to approve 2025 statutory and consolidated accounts showing a net accounting loss of EUR 207,965,630.56, to carry this loss forward, bringing the debit balance of retained earnings to EUR 583,594,899.42, and to confirm that no dividend will be paid. The agenda includes say‑on‑pay approvals, renewal and appointment of directors, and a board fee pool of up to EUR 1,500,000. Shareholders are also asked to authorize a share buyback of up to 10% of outstanding shares at a maximum price of EUR 40 per share and to grant multiple capital authorization mandates, including share issues with and without preemptive rights up to a combined nominal cap of EUR 2,000,000 and related debt securities up to EUR 500,000,000. Further resolutions cover employee and officer equity incentives, an at‑the‑market program framework, and potential capital reductions via share cancellations. One resolution notes that shareholders’ equity has fallen below half of share capital and records the decision not to dissolve the company, requiring equity to be restored within the legal timeframe.